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Abstract: Antiplatelet drug resistance is one of the urgent issues in current cardiovascular 
medicine. Many platelet function tests have been used to define responsiveness of patients with 
cardiovascular disease to aspirin and clopidogrel. In most studies, cut-off values of platelet 
function tests for defining responsiveness to antiplatelets were chosen arbitrarily. Different 
tests provided wide-ranging figures of the prevalence of aspirin and clopidogrel resistance, 
suggesting poor correlation between currently available platelet function tests. Measurement 
of platelet size seems to be a promising approach for monitoring antiplatelet drug therapy. 
This commentary highlights some limitations of studies on aspirin and clopidogrel resistance 
in patients undergoing coronary interventions.
Keywords: aspirin, clopidogrel, resistance, cardiovascular disease, platelet function tests
Antiplatelet resistance is one of the urgent issues in current cardiovascular medicine. 
With the wide-spread clinical use of low-dose aspirin, it has become possible to sub-
stantially reduce incidence of vascular thrombotic events in patients with cardiovascular 
and cerebrovascular disease. Antithrombotic Trialists’ Collaboration provided robust 
evidence distinguishing 75 to 150 mg/daily aspirin therapy as an effective means for 
secondary cardiovascular prevention.1 At the same time, it has become clear that a 
substantial proportion of patients at high risk of cardiovascular events do not benefit 
from aspirin monotherapy or even aspirin and clopidogrel dual therapy.2 In other words, 
antiplatelets fail to suppress their targets and to prevent cardiovascular events in a 
cohort of patients owing to several biochemical and clinical factors. The latter study 
led to emergence of a new phenomenon of ‘aspirin and/or clopidogrel resistance’ and 
prompted a search for platelet function tests that could reliably monitor suppression 
of antiplatelet targets.
Numerous studies using different platelet function tests provided estimates of 
the prevalence ranging from 5.5% to 60% for aspirin resistance2 and 16.8% to 21% 
for clopidogrel resistance.3,4 Not surprisingly, replacement of aspirin monotherapy 
with dual (aspirin plus clopidogrel) or even triple antiplatelet therapy (aspirin plus 
clopidogrel plus dipyridamol or another more potent agent) was suggested. The initial 
strategy of the replacement, however, became more cautious when more research data 
on putative mechanisms of the resistance accumulated and research methodology of 
initial studies analyzed.
It appears that aspirin non-compliance can underlie occurrence of thrombotic 
complications in a large proportion of patients. At least one-third of patients catego-
rized as having aspirin resistance turned out to be simply those who neglect taking Vascular Health and Risk Management 2010:6 110
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aspirin daily.5 Other important and perhaps not less frequent 
mechanical causes of so called aspirin resistance can be 
co-administration of other non-steroidal anti-inflammatory 
drugs or intake of less bioavailable enteric-coated aspirin 
instead of easy dispersible tablets.6 Moreover, antiplatelet 
effects of aspirin are minimal, if not absent, in the case of 
infections with overproduction of C-reactive protein (CRP).7 
Similarly, it is unlikely to achieve substantial antithrombotic 
effects with low-dose aspirin in inflammatory arthritis, 
diabetes, and in condition associated with surgical stress, 
where platelet turnout (thrombocytosis), oxidative stress and 
CRP elevation counteract and outweigh cyclooxygenase-1 
(COX-1) dependent effect of aspirin.2
In the latest review on aspirin and clopidogrel resistance, 
Sharma et al8 raised a question of why we still do not monitor 
platelet function in patients taking antiplatelets, and presented 
several tests for tailoring antiplatelet therapy and stratifying 
patients into non-responsive, hyporesponsive, and responsive 
to aspirin and clopidogrel. The issue has been previously 
discussed and many drawbacks of each platelet function test 
have been identified.9 As a result, none of the currently avail-
able tests, including platelet aggregometry and the Platelet 
Function Analyzer-100TM (PFA-100TM) can be recommended 
for clinical practice.
Optical aggregometry, a gold standard of platelet func-
tion testing, which was used in most studies on aspirin and 
clopidogrel resistance, requires a relatively large amount 
of blood, does not take into account interaction of platelets 
with other cells, and can yield unpredictable results owing to 
changes of platelet activity markers during blood sampling, 
storing, separating, and diluting preparing platelet reach 
plasma, and processing samples.
The PFA-100TM is a relatively simple test based on blood 
clotting in shear stress condition. This test, however, is not 
entirely dependent on platelet function, and measurement of 
other predictors of thrombosis initiated by shear stress, such 
as von Willebrand factor, is strongly recommended.
It should be stressed that the VerifyNowTM is a modified 
platelet aggregation test, which enables platelet activation 
during blood sampling and processing to be avoided and 
specifically assesses the blockade of either arachidonic acid 
or purinergic pathways in platelets.
Another highly specific test presented is vasodilator-
stimulated phosphoprotein (VASP) phosphorylation flow 
cytometry test, which is used in studies of clopidogrel 
resistance. However, this and other flow cytometry tests are 
expensive and should be used only by experienced labora-
tory personnel.
The most challenging problem in terms of platelet func-
tion testing for defining responsiveness to antiplatelets seems 
to be the lack of correlation between results of the majority 
of currently available tests. Remarkably, Lordkipanidze 
et al10 used 6 different tests and obtained varying degrees of 
the prevalence of aspirin resistance: the lowest (6.7%) was 
detected by the VerifyNow point-of-care test and the high-
est (59.5%) by the PFA-100 test. Similarly, poor correlation 
was reported between 4 different tests in another study on 
clopidogrel resistance.11
There is, however, a possibility of using relatively simple 
and readily available tests, such as measurement of mean 
platelet volume (MPV) by automated cell counter, high-
lighted in a few recent studies on antiplatelet resistance.12–14 
This test can be viewed as an alternative to many expensive 
new tests. MPV is a surrogate marker of platelet function and 
valuable prognostic parameter: the large size of platelets is 
known to be associated with poor vascular prognosis. MPV 
values are predetermined by size and activity of platelets 
newly released from bone marrow and remain stable through-
out their life in the circulation. It is, therefore, likely that 
MPV measurement may be especially useful for monitoring 
response to antiplatelets suppressing low-grade inflammation 
and megakaryopoiesis (eg, clopidogrel). Actually, in one 
small study, aspirin was shown to exert an insignificant effect 
on MPV.15 However, a more recent study using MPV along 
with VerifyNow tests for defining responsiveness to aspirin 
and clopidogrel showed strong correlation between these 
tests, which may indicate the utility of MPV measurement 
for predicting antiplatelet resistance and related thrombotic 
events.16 After all, the most important factor limiting wide-
spread use of MPV is the risk of platelets swelling in test 
tubes containing ethylene diamine tetraacetic acid and the 
distortion of the real picture of platelet activity with delayed 
processing of samples (after 1–2 hours of blood sampling).
Arbitrary chosen cut-off values of platelet function tests is 
another big issue in the context of accurately defining (non) 
responsiveness or resistance to antiplatelets. An appropriate 
example of the arbitrary and highly controversial definition 
of aspirin resistance is an approach used in a landmark 
prospective study on aspirin resistance by Gum et al who 
detected aspirin resistance in 5.2% of patients with stable 
coronary artery disease based on optical platelet aggrega-
tion of more than 20% with 0.5 mg/mL of arachidonic acid 
and, surprisingly, more than 70% with 10 µM of adenosine 
diphosphate.17
Controversies also surround appropriateness of linking 
short- and long-term thrombotic events in patients undergoing Vascular Health and Risk Management 2010:6 111
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coronary invasive procedures with baseline values of platelet 
function tests and measures of antiplatelet resistance. Firstly, 
platelet function is not constant over time and prospective 
follow-up of the patients should encompass repetitive assess-
ments of platelet inhibition parameters to clarify possible 
association between different measures of platelet inhibi-
tion and thrombotic events. Secondly, patients undergoing 
coronary interventions are exposed to many antithrombotic 
and other drugs interfering with COX-1 dependent action 
of aspirin and, therefore, it seems inappropriate to judge the 
presence or absence of aspirin resistance without excluding 
confounding factors. Thirdly, thrombotic events after coronary 
stenting or bypass grafting can depend strongly on the type of 
stents and surgical techniques used, but not on the efficiency 
of antiplatelet therapy. Finally, to what extent ethnicity and 
co-morbidities (eg, heart failure, diabetes, hypertension, 
and chronic inflammatory disorders) affect platelet func-
tion and underlie responsiveness to antiplatelets in those 
undergoing coronary interventions still remain to be deter-
mined. Unfortunately, these issues have not been sufficiently 
addressed in recent studies on aspirin resistance.8,18,19
In conclusion, aspirin and clopidogrel are currently widely 
used antiplatelet agents with relatively safe profiles and 
proven efficiency. Occurrence of thrombotic complications, 
despite mono or dual antiplatelet therapy, in most patients with 
stable cardiovascular disease and those undergoing coronary 
interventions has been linked to antiplatelet resistance. Mul-
tiple laboratory tests have been used to identify those who fail 
to respond fully to platelet-inhibiting effects of aspirin and 
clopidogrel and attempts have made to overcome the resis-
tance by adding more powerful agents. It has become evident 
that intensive antiplatelet therapy, particularly with the novel 
thienopyridine agent prasugrel instead of clopidogrel, is justi-
fied in those at high risk of ischemic events.20 Nonetheless, it is 
not clear whether this or any other aggressive approach with 
powerful suppression of platelets is applicable in conditions 
associated with the risk of bleeding (eg, in diabetes, heart 
failure, or chronic inflammatory disorders).
More efforts are needed to standardize methods for defin-
ing laboratory responsiveness to old and new antiplatelet 
agents, to provide consensual definition of antiplatelet resis-
tance, and to conduct prospective studies with serial platelet 
function assessment to ascertain links between laboratory 
and clinically defined antiplatelet resistance. Standardization 
should, first, imply selection of platelet function tests with 
minimal intra- and interassay variability (eg, MPV measure-
ment), which can reliably identify ‘true’ laboratory defined 
resistance in research studies. Whether or not these tests can 
be recommended for clinical practice is subject to the results 
of future prospective studies, in which monitoring of platelet 
function should be combined with quantification of markers 
of inflammation, oxidative stress, and cardiovascular risk 
factors, and should be associated with a sufficient number 
of cardiovascular events.
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